Dossier
Lipfendra
Coverage of Lipfendra in the Nexus archive.
- Drugmaker Merck announces approval of new cholesterol-fighting drug
Merck received FDA approval for Lipfendra, a PCSK9 inhibitor that serves as an alternative to statins for managing high LDL cholesterol. Statins, while widely prescribed, can cause side effects like muscle aches and may not sufficiently lower cholesterol levels for some patients.
- FDA approves new pill to slash cholesterol levels
The FDA approved enlicitide (brand name Lipfendra), a daily pill that lowers cholesterol levels more effectively than statins. The drug is produced by pharmaceutical company Merck.
- Merck won FDA approval for the first cholesterol pill to rival powerful injectables
Merck received FDA approval for Lipfendra, a once-daily cholesterol pill that reduced LDL cholesterol by up to 59% in late-stage trials, making it a competitor to existing injectable treatments.